Medicine Matters Rheumatology

Results of two studies emphasize the important of taking pain and comorbidities into account when treating patients with spondyloarthritis.

Results of a phase IIa trial support further investigation of the selective URAT1 inhibitor verinurad in combination with febuxostat for the treatment of gout.

An international taskforce has developed consensus recommendations for treating juvenile idiopathic arthritis to target.

Treatment with the tumor necrosis factor inhibitor certolizumab pegol during pregnancy is not likely to be associated with teratogenic effects, researchers report.

Extension results from the ABILITY-1 trial support the long-term benefits of adalimumab for patients with nonradiographic axial spondyloarthritis.

Researchers have found that the long-term retention rate for a first tumor necrosis factor inhibitor is favorable in patients with spondyloarthritis.